Catalyst
Slingshot members are tracking this event:
Clovis (CLVS) Presents Data on Two Phase 2 Studies of Rucaparib in Treatment-Resistant Ovarian Cancer at the European Society for Medical Oncology 2016 Congress
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CLVS |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 07, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2, Ariel2, Study 10, European Society For Medical Oncology, Rucaparib, Treatment-resistant Ovarian Cancer
